Traditional Chinese compound for curing central obesity and nonalcoholic fatty liver disease and preparation method thereof

Abstract

The invention discloses a traditional Chinese compound preparation for curing nonalcoholic fatty liver and central obesity and is characterized in that the compound preparation is prepared by adding medicinal excipient to the extractives of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris, wherein the weight mixture ratio of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris is 1-4:1:1-3:1-3:1-3. Proved by clinical trial, the drug combination of the invention can reduce the abdominal perimeter ofpatients, lower the AUC (area under curve) of triglyceride after dinner, improve the CT specific value of liver and spleen and bring down the transaminase level of liver with evident treatment effect. Verified by clinical research, the compound can obviously increase the insulin sensitivity of patients, lower inflammatory factor level and improve fibrinolysis-blood clotting function. Shown by experimental research, the drug of the invention can enhance the sensitivity of fat and muscle cells to insulin and has significant value in treating nonalcoholic fatty liver and central obesity which take insulin resistance as fundamental pathological link.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine compound for treating central obesity and non-alcoholic fatty liver and a preparation method thereof. Background technique [0002] According to the working definition of metabolic syndrome by the International Diabetes Federation (IDF), central obesity is a prerequisite for determining metabolic syndrome and is the most intuitive external sign of insulin resistance. The standard of Chinese central obesity defined by IDF is that the abdominal circumference of men is greater than 90cm, and the abdominal circumference of women is greater than 80cm; and according to the "Guidelines for the Control of Overweight and Obesity in Chinese Adults (Trial)" issued by the Department of Disease Control of the Ministry of Health in 2003 , the standard of central obesity for Chinese people is ≥85cm for men and ≥80cm for women. [0003] Non-alcoholic f...

AI Technical Summary

Problems solved by technology

Metformin can increase blood lactic acid levels; rosiglitazone itself can increase body weight, and has adverse reactions such as headache and edema, and has recently been reported to increase the risk of cardiovascular death

Fatty liver patients are often accompanied by hyperlipidemia, and lipid-regulating therapy is an ideal way to improve lipid metabolism disorders. Fatty liver patients already have liver damage, which greatly limits the application of lipid-lowering drugs

Therefore, there is no ideal chemical drug treatment for central obesity and non-alcoholic fatty liver.